Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03103568
Other study ID # Sobi.NTBC-006
Secondary ID 2016-004297-17
Status Completed
Phase Phase 1
First received March 27, 2017
Last updated August 9, 2017
Start date March 28, 2017
Est. completion date July 24, 2017

Study information

Verified date August 2017
Source Swedish Orphan Biovitrum
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An open-label, non-randomized, 2-arm, 2-period fixed sequence phase 1 study to evaluate the potential inhibition of nitisinone on cytochrome P450 2C9, 2D6, and 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers


Description:

This is an open-label, non-randomized, 2-arm, 2-period fixed-sequence drug-drug interaction study in a total of 36 (18 in each arm) male and female healthy volunteers.

The study consists of: Screening, Period 1 (substrates only), Period 2 (substrates + nitisinone) and Follow-up. In the screening period, subjects will be assessed for eligibility. Eligible subjects will be assigned to one of two treatment arms. In Arm A, the potential inhibition of nitisinone on CYP2C9, CYP2D6, and CYP2E1 will be investigated. In Arm B, the possible combined effect of nitisinone on the renal transporters OAT1 and OAT3 will be investigated.

In Period 1, the subjects will receive a single dose of a CYP cocktail of 3 substrates (Arm A) or an OAT1/OAT3 substrate (Arm B). Substrate plasma concentrations will be measured for determination of substrate PK; for up to 48 hours in Arm A and for 8 hours in Arm B.

During Period 2, the treatment and assessments will vary slightly between the 2 treatment arms. Nitisinone will be administered for 14 days, without co-administration of any substrate, in order to reach steady state and the recommended target plasma concentration, before the interaction with the substrates is studied.

In Arm A, Period 2, subjects will receive nitisinone for 16 consecutive days (14 days on nitisinone only and two days on nitisinone + substrate). Nitisinone steady state PK will be determined based on plasma and urine samples collected during one dosage interval at steady state, on the day before co-administration of the substrates. Nitisinone will then be administered together with the CYP substrates, and plasma samples for determination of their PK will be collected as in Period 1. There will be a final nitisinone dose on the day after substrate administration in order to maintain therapeutic levels throughout the 48-hour sampling period.

In Arm B, Period 2, subjects will receive nitisinone for 15 consecutive days (14 days on nitisinone only and one day on nitisinone + substrate). No nitisinone steady state PK characterization will be conducted in this arm. On the last treatment day, the subjects will receive nitisinone together with the OAT1/OAT3 substrate. This will be followed by 8 hours of blood sampling for determination of substrate PK.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date July 24, 2017
Est. primary completion date June 10, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

1. Healthy male and female volunteers, 18 - 55 years of age inclusive, who are judged by the investigator to be healthy on the basis of a pre-study physical examination, which includes clinical chemistry, hematology and urinalysis, vital signs (pulse and blood pressure), and ECG.

2. Female subject must be either:

a. Of none childbearing potential: i. post-menopausal (defined as at least 1 year without any menstruation without an alternative medical cause) , prior to Screening, or ii. documented surgically sterile or status post hysterectomy (at least 1 month prior to Screening).

b. Or, if of childbearing potential, i. must have a negative urine/serum pregnancy test at Screening, and ii. must be using highly effective methods of birth control [Acceptable forms of birth control include: 1) Placement of an intrauterine device (IUD) or intrauterine system (IUS). The devices must not release any hormones. (Note: The IUD must have a failure rate < 1 %) 2) the subject's male partner has undergone effective surgical sterilization before the female subject entered the clinical trial and he is the sole sexual partner of the female subject during the clinical trial. 3) Observe abstinence (acceptable only if it is the subject's usual lifestyle). ] (failure rate < 1% per year when used consistently and correctly) at least 3 months prior to Screening until 4 weeks after study termination in combination with an approved barrier method [Approved barrier methods of contraception include: condom (without spermicidal foam/gel/film/cream/suppository or fat- or oil-containing lubricants), or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.]. Women should be informed of the potential risks associated with becoming pregnant while enrolled.

3. Male subjects must agree to use a condom when having sexual intercourse with female partners of childbearing potential during treatment and up to 4 weeks after the last dose of study treatment.

4. Body weight 64 to 100 kg.

5. Body mass index (BMI) 18 - 30 kg/m2

6. Signed informed consent.

Exclusion Criteria:

1. Any medical condition which in the opinion of the investigator makes the subject unsuitable for inclusion.

2. Recent history or presence of clinically significant gastrointestinal, hepatic, renal, cardiovascular, hematological, metabolic, urological, pulmonary, neurological or psychiatric disorder.

3. History of hypoglycemia.

4. Current keratopathy, or other clinically relevant abnormalities, found by ophthalmologic slit-lamp examination.

5. Poor or ultra-rapid metabolism of CYP2D6 substrates confirmed by genotyping (exclusion criteria for Arm A only).

6. History of allergy, hypersensitivity or known contraindication to any of the drugs, or their excipients, used in this study.

7. History of sulfonamide allergy.

8. Continuous use of any non-topical medication within 1 month, over-the-counter preparations, herbal remedies , and all other medication within 14 days or less than 5 times the half-life of that medication, whichever is the longer, prior to first intake of an IMP.

9. Daily smoking > 10 cigarettes.

10. Daily consumption of more than 5 cups of coffee.

11. History of drug and/or alcohol abuse.

12. Positive drug screen or alcohol test.

13. Positive screens for HBsAg, anti-HCV, anti-HBc Ab, HepC, HIV 1 2 antibodies.

14. Pregnancy or breast feeding.

15. Female subjects using hormonal contraceptives.

16. Enrollment in another concurrent clinical study, or intake of an experimental drug, within 3 months prior to inclusion in this study.

17. Donation of more than 400 mL of blood within 90 days prior to drug administration or donation of more than 1.5 liters of blood in the 10 months prior to first intake of an IMP.

18. Foreseeable inability to cooperate with given instructions or study procedures.

19. Inability to give written informed consent or to comply fully with the protocol.

20. Vulnerable subjects, e.g., subjects kept in detention.

21. Soldiers, investigator, employees of the Sponsor or CRO.

22. Subject is not able to read, write and speak German.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nitisinone in Arm A
4 capsules of 20 mg nitisinone (80 mg) is given once daily for 17 days.
Tolbutamide
A 500 mg tablet is given as single oral dose 2 weeks apart.
Metoprolol
A 50 mg tablet of metoprolol tartrate is given as single oral dose 2 weeks apart.
Chlorzoxazone
A 250 mg tablet is given as single oral dose 2 weeks apart.
Furosemide
A single intravenous dose of 20 mg administered as an i.v. infusion is given 2 weeks apart.
Nitisinone in Arm B
4 capsules of 20 mg nitisinone (80 mg) is given once daily for 16 days.

Locations

Country Name City State
Germany PAREXEL EPCU Berlin Berlin

Sponsors (2)

Lead Sponsor Collaborator
Swedish Orphan Biovitrum Parexel

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area under the curve (AUC) infinity for CYP2C9 (tolbutamide) substrate The primary outcome measure is to investigate the AUC for tolbutamide taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to tolbutamide administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose.
Primary AUC infinity for CYP2D6 (metoprolol) substrate The primary outcome measure is to investigate the AUC for metoprolol taken as a single dose with and without presence of nitisinone. Blood samples will be obtained the following times in relation to metoprolol administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7, 9, 11, 15 and 23 h post-dose.
Primary AUC infinity for CYP2E1 (chlorzoxazone) substrate The primary outcome measure is to investigate the AUC for chlorzoxazone taken with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to chlorzoxazone administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7, 9 and 11 h post-dose.
Primary AUC infinity for OAT1/OAT3 (furosemide) substrate The primary outcome measure is to investigate the AUC for furosemide with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to furosemide administration: predose and, 5, 10, 15, 20, 30, 45 minutes, 1, 2, 3, 4, 6, and 8 hours post-dose
Secondary Maximum concentration (Cmax) for CYP2C9 (tolbutamide) substrate A secondary outcome measure is to investigate Cmax for tolbutamide taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to tolbutamide administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose.
Secondary Time to maximum concentration (tmax) for CYP2C9 (tolbutamide) substrate A secondary outcome measure is to investigate tmax for tolbutamide taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to tolbutamide administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose.
Secondary AUC last for CYP2C9 (tolbutamide) substrate A secondary outcome measure is to investigate AUC last for tolbutamide taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to tolbutamide administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose.
Secondary Residual area for CYP2C9 (tolbutamide) substrate A secondary outcome measure is to investigate the residual area for tolbutamide taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to tolbutamide administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose.
Secondary terminal half-life for CYP2C9 (tolbutamide) substrate A secondary outcome measure is to investigate the terminal half-life for tolbutamide taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to tolbutamide administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose.
Secondary Cmax for CYP2D6 (metoprolol) substrate A secondary outcome measure is to investigate Cmax for metoprolol taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to metoprolol administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7, 9, 11, 15 and 23 h post-dose.
Secondary tmax for CYP2D6 (metoprolol) substrate A secondary outcome measure is to investigate tmax for metoprolol taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to metoprolol administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7, 9, 11, 15 and 23 h post-dose.
Secondary AUC last for CYP2D6 (metoprolol) substrate A secondary outcome measure is to investigate AUClast for metoprolol taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to metoprolol administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7, 9, 11, 15 and 23 h post-dose.
Secondary Residual area for CYP2D6 (metoprolol) substrate A secondary outcome measure is to investigate the residual area for metoprolol taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to metoprolol administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7, 9, 11, 15 and 23 h post-dose.
Secondary terminal half-life for CYP2D6 (metoprolol) substrate A secondary outcome measure is to investigate the terminal half-life for metoprolol taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to metoprolol administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7, 9, 11, 15 and 23 h post-dose.
Secondary Cmax for CYP2E1 (chlorzoxazone) substrate A secondary outcome measure is to investigate Cmax for chlorzoxazone taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to chlorzoxazone administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7, 9 and 11 h post-dose.
Secondary tmax for CYP2E1 (chlorzoxazone) substrate A secondary outcome measure is to investigate tmax for chlorzoxazone taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to chlorzoxazone administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7, 9 and 11 h post-dose.
Secondary AUC last for CYP2E1 (chlorzoxazone) substrate A secondary outcome measure is to investigate AUC last for chlorzoxazone taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to chlorzoxazone administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7, 9 and 11 h post-dose.
Secondary Residual area for CYP2E1 (chlorzoxazone) substrate A secondary outcome measure is to investigate the residual area for chlorzoxazone taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to chlorzoxazone administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7, 9 and 11 h post-dose.
Secondary terminal half-life for CYP2E1 (chlorzoxazone) substrate A secondary outcome measure is to investigate the terminal half-life for chlorzoxazone taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to chlorzoxazone administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7, 9 and 11 h post-dose.
Secondary Cmax for OAT1/OAT3 (furosemide) substrate A secondary outcome measure is to investigate Cmax for furosemide taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to furosemide administration: predose and, 5, 10, 15, 20, 30, 45 minutes, 1, 2, 3, 4, 6, and 8 hours post-dose
Secondary tmax for OAT1/OAT3 (furosemide) substrate A secondary outcome measure is to investigate tmax for furosemide taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to furosemide administration: predose and, 5, 10, 15, 20, 30, 45 minutes, 1, 2, 3, 4, 6, and 8 hours post-dose
Secondary AUC last for OAT1/OAT3 (furosemide) substrate A secondary outcome measure is to investigate AUC last for furosemide taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to furosemide administration: predose and, 5, 10, 15, 20, 30, 45 minutes, 1, 2, 3, 4, 6, and 8 hours post-dose
Secondary Residual area for OAT1/OAT3 (furosemide) substrate A secondary outcome measure is to investigate the residual area for furosemide taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to furosemide administration: predose and, 5, 10, 15, 20, 30, 45 minutes, 1, 2, 3, 4, 6, and 8 hours post-dose
Secondary terminal half-life for OAT1/OAT3 (furosemide) substrate A secondary outcome measure is to investigate the terminal half-life for furosemide taken as a single dose with and without the presence of nitisinone. Blood samples will be obtained the following times in relation to furosemide administration: predose and, 5, 10, 15, 20, 30, 45 minutes, 1, 2, 3, 4, 6, and 8 hours post-dose
Secondary 24-hour plasma concentration profile for nitisinone at steady state. A secondary outcome measure is to investigate the plasma concentration profile for nitisinone at steady state. Blood samples will be collected during 24 hours when steady state has been reached during the following time points: pre-dose and, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16 and 24 h postdose.
Secondary 24 hour renal excretion for nitisinone at steady state. A secondary outcome measure is to investigate the urine excretion of nitisinone at steady state. Urine will be collected for 24 hours post nitisinone dosing and during the following time intervals: 0-3 hours, 3-6 hours, 6-9 hours, 9-12 hours and 12-24 hours.
See also
  Status Clinical Trial Phase
Completed NCT05574374 - Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects Phase 1
Completed NCT04557397 - Fruquintinib CYP3A Inhibitor and Inducer Study Phase 1
Completed NCT06031454 - Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin Phase 1
Completed NCT05137600 - A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects Phase 1
Recruiting NCT06119958 - Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects Phase 1
Active, not recruiting NCT05812404 - Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects Phase 1
Completed NCT04606537 - Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects Phase 1
Completed NCT04939467 - Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Completed NCT04542252 - Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects Phase 1
Enrolling by invitation NCT06037564 - B-free Multistage Trial Phase 4
Completed NCT05123820 - Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470 Phase 1
Recruiting NCT04840862 - Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor Phase 4
Completed NCT04814498 - Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Completed NCT01350921 - Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers Phase 1
Completed NCT04840641 - Flucloxacillin as an Inducer of CYP-enzymes Phase 1
Completed NCT05845567 - The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2) Phase 1
Completed NCT05304845 - Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects Phase 1
Completed NCT05860114 - Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3) Phase 1
Completed NCT04776499 - Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers Phase 1
Completed NCT03909529 - Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug) Phase 1